Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Omacetaxine Mepesuccinate

FDA-approved product (powder, subcutaneous), marketed as Synribo.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Omacetaxine Mepesuccinate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Other antineoplastic agents
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA59.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli37.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Omacetaxine Mepesuccinate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Omacetaxine Mepesuccinate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS

    NCT03564873 · start 2018-09-17

    Registered record
    Registry ID
    NCT03564873
    Conditions
    High Grade Myelodysplastic Syndromes
    Interventions
    Omacetaxine; Azacitidine; Omacetaxine; Azacitidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2018-09-17
    Completion
    2027-06
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHigh Grade Myelodysplastic Syndromes
    InterventionOmacetaxine; Azacitidine; Omacetaxine; Azacitidine
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • DCHA as Postremission Therapy for AML With t(8;21)

    NCT03453255 · start 2018-01-01

    Registered record
    Registry ID
    NCT03453255
    Conditions
    Chemotherapy
    Interventions
    Chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2018-01-01
    Completion
    2020-12-31
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChemotherapy
    InterventionChemotherapy
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD

    NCT03135054 · start 2017-10-01

    Registered record
    Registry ID
    NCT03135054
    Conditions
    AML; FLT3-ITD Mutation
    Interventions
    Quizartinib; Omacetaxine Mepesuccinate Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2017-10-01
    Completion
    2021-10-01
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAML; FLT3-ITD Mutation
    InterventionQuizartinib; Omacetaxine Mepesuccinate Injection
    PhasePhase 2
    Registry statusUnknown

  • Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD

    NCT03170895 · start 2017-07-01

    Registered record
    Registry ID
    NCT03170895
    Conditions
    AML; FLT3-ITD Mutation
    Interventions
    Sorafenib; Omacetaxine Mepesuccinate Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-07-01
    Completion
    2020-03-01
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAML; FLT3-ITD Mutation
    InterventionSorafenib; Omacetaxine Mepesuccinate Injection
    PhasePhase 2
    Registry statusCompleted

  • A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)

    NCT02835794 · start 2016-08

    Registered record
    Registry ID
    NCT02835794
    Conditions
    Myelodysplastic Syndromes
    Interventions
    Omacetaxine; Azacitidine; G-CSF
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2016-08
    Completion
    2018-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyelodysplastic Syndromes
    InterventionOmacetaxine; Azacitidine; G-CSF
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn

  • AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients

    NCT02440568 · start 2015-06-05

    Registered record
    Registry ID
    NCT02440568
    Conditions
    Acute Myeloid Leukemia
    Interventions
    Cytarabine; Idarubicin; Omacetaxine mepesuccinate; Omacetaxine mepesuccinate; Omacetaxine mepesuccinate; Omacetaxine mepesuccinate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2015-06-05
    Completion
    2018-11-30
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia
    InterventionCytarabine; Idarubicin; Omacetaxine mepesuccinate; Omacetaxine mepesuccinate +2 more
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure

    NCT02159872 · start 2015-05-18

    Registered record
    Registry ID
    NCT02159872
    Conditions
    Leukemia
    Interventions
    Omacetaxine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-05-18
    Completion
    2020-04-14
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia
    InterventionOmacetaxine
    PhasePhase 2
    Registry statusCompleted

  • Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

    NCT02029417 · start 2014-07

    Registered record
    Registry ID
    NCT02029417
    Conditions
    Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13; q22); Adult Acute Myeloid Leukemia With t(16; 16)(p13; q22); Adult Acute Myeloid Leukemia With t(8; 21)(q22; q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia
    Interventions
    cytarabine; omacetaxine mepesuccinate; decitabine; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2014-07
    Completion
    2015-12
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a) +18 more
    Interventioncytarabine; omacetaxine mepesuccinate; decitabine; laboratory biomarker analysis
    PhasePhase 2
    Registry statusTerminated

  • Omacetaxine for Consolidation and Maintenance

    NCT01873495 · start 2013-05

    Registered record
    Registry ID
    NCT01873495
    Conditions
    Acute Myelogenous Leukemia (AML)
    Interventions
    Omacetaxine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2013-05
    Completion
    2018-07
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myelogenous Leukemia (AML)
    InterventionOmacetaxine
    PhasePhase 2
    Registry statusTerminated

  • Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS

    NCT01417767 · start 2011-09

    Registered record
    Registry ID
    NCT01417767
    Conditions
    Myelodysplastic Syndromes
    Interventions
    CHG regimen; 5-aza-deoxycytidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2011-09
    Completion
    2013-09
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyelodysplastic Syndromes
    InterventionCHG regimen; 5-aza-deoxycytidine
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

    NCT01272245 · start 2011-07

    Registered record
    Registry ID
    NCT01272245
    Conditions
    Leukemia
    Interventions
    Omacetaxine; Cytarabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-07
    Completion
    2017-01
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia
    InterventionOmacetaxine; Cytarabine
    PhasePhase 2
    Registry statusCompleted

  • Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors

    NCT00675350 · start 2008-04

    Registered record
    Registry ID
    NCT00675350
    Conditions
    Hematologic Tumors
    Interventions
    Omacetaxine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-04
    Completion
    2009-01
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHematologic Tumors
    InterventionOmacetaxine
    PhasePhase 1
    Registry statusCompleted

  • Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML

    NCT00462943 · start 2007-03-07

    Registered record
    Registry ID
    NCT00462943
    Conditions
    Chronic Myeloid Leukemia
    Interventions
    Omacetaxine mepesuccinate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-03-07
    Completion
    2013-06-27
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myeloid Leukemia
    InterventionOmacetaxine mepesuccinate
    PhasePhase 2
    Registry statusCompleted

  • Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)

    NCT00114959 · start 2005-10

    Registered record
    Registry ID
    NCT00114959
    Conditions
    Myeloid Leukemia, Chronic; Myeloid Leukemia, Chronic, Accelerated-Phase; Blast Phase; Myeloid Leukemia, Chronic, Chronic-Phase
    Interventions
    Homoharringtonine; Imatinib Mesylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2005-10
    Completion
    2009-03
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyeloid Leukemia, Chronic; Myeloid Leukemia, Chronic, Accelerated-Phase; Blast Phase; Myeloid Leukemia, Chronic, Chronic-Phase
    InterventionHomoharringtonine; Imatinib Mesylate
    PhasePhase 2
    Registry statusTerminated

  • Efficacy Analysis of Comparison of CAMS（Chinese Academy of Medical Sciences）-2005 Trial and CAMS-2009 Trial for Pediatric Acute Myeloid Leukemia

    NCT03165851 · start 2005-04-10

    Registered record
    Registry ID
    NCT03165851
    Conditions
    Acute Myeloid Leukemia, Pediatric
    Interventions
    Risk-stratified therapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2005-04-10
    Completion
    2015-12-31
    Enrolment
    320

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia, Pediatric
    InterventionRisk-stratified therapy
    PhaseNot recorded
    Registry statusCompleted